Induction of antigen-specific humoral tolerance by rAAV-mediated delivery of CTLA4-Ig-antigen fusion molecules

Website
http://purl.org/au-research/grants/nhmrc/477101

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.

Funded Activity Summary

There are many medical situations where immune suppression is required. Available methods lack specificity and risk infection, drug-related side-effects and cancer. We have discovered a novel way of suppressing immunity such that only unwanted responses are eliminated. This involves virus-mediated delivery of antigen fused to CTLA4-Ig. We plan to test this strategy in the context of gene therapy, to work out how it works and to optimise the approach. Success will have broad health implications.

Funded Activity Details

Start Date: 2008

End Date: 2010

Funding Scheme: NHMRC Project Grants

Funding Amount: $524,456.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Gene Therapy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Related Researchers

No related researchers have been discovered for grant Induction of antigen-specific humoral tolerance by rAAV-mediated delivery of CTLA4-Ig-antigen fusion molecules.

Related Organisations

No related organisations have been discovered for grant Induction of antigen-specific humoral tolerance by rAAV-mediated delivery of CTLA4-Ig-antigen fusion molecules.